Galectin Therapeutics Inc.
GALT Real Time Price USDRecent trades of GALT by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by GALT's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
GALT Revenue by Segment or Geography
No Revenue by Segment data for this ticker
No Revenue by Geography data for this ticker
New patents grants
-
Patent Title: Methods for treatment of arthritis Aug. 16, 2022
-
Patent Title: Composition of novel carbohydrate drug for treatment of human diseases Oct. 13, 2020
-
Patent Title: Galactose-pronged polysaccharides in a formulation for antifibrotic therapies Aug. 18, 2020
-
Patent Title: Composition of novel carbohydrate drug for treatment of human diseases Sep. 24, 2019
-
Patent Title: Method for enhancing specific immunotherapies in cancer treatment Sep. 03, 2019
-
Patent Title: Composition of novel carbohydrate drug for treatment of human diseases May. 22, 2018
-
Patent Title: Method for treatment of pulmonary fibrosis May. 15, 2018
-
Patent Title: Method for enhancing specific immunotherapies in cancer treatment Jan. 23, 2018
-
Patent Title: Galacto-rhamnogalacturonate compositions for the treatment of diseases associated with elevated inducible nitric oxide synthase Sep. 19, 2017
-
Patent Title: Composition of novel carbohydrate drug for treatment of human diseases May. 16, 2017
-
Patent Title: Method for treatment of pulmonary fibrosis May. 17, 2016
-
Patent Title: Galactose-pronged polysaccharides in a formulation for antifibrotic therapies Dec. 01, 2015
-
Patent Title: Composition of novel carbohydrate drug for treatment of human diseases Feb. 24, 2015
-
Patent Title: Compositions of novel carbohydrate drug for treatment of human diseases Oct. 28, 2014
-
Patent Title: Galactose-pronged carbohydrate compounds for the treatment of diabetic nephropathy and associated disorders Sep. 09, 2014
-
Patent Title: Galactose-pronged polysaccharides in a formulation for antifibrotic therapies May. 13, 2014
-
Patent Title: Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease Feb. 25, 2014
-
Patent Title: Galactose-pronged polysaccharides in a formulation for antifibrotic therapies Feb. 05, 2013
-
Patent Title: Galactose—pronged polysaccharides in a formulation for antifibrotic therapies Aug. 07, 2012
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to GALT
Number of mentions of GALT in WallStreetBets Daily Discussion
Recent picks made for GALT stock on CNBC
ETFs with the largest estimated holdings in GALT
|
Shareholder
|
Shares Held
|
|---|
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view GALT Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.